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Fabry's disease is an X-linked recessive genetic defi•
ciency of the enzyme alpha-galactosidase A, which leads 
to the pathologic deposition of neutral glycosphingolipids 
in Iysosomes of the vascular endothelium of the heart, 
brain and kidney. The disease is progressive in hemi•
zygous male patients, with increasing involvement of the 
major organs leading to death. Because cardiac involve•
ment is a constant feature, echocardiograms were per•
formed on 35 patients with Fabry's disease, 23 hemi•
zygotes (aged 28.6 ± 14 years) and 12 heterozygotes 
(aged 31.6 ± 6 years), to determine whether cardiac 
involvement could be detected noninvasively. 
The results demonstrated that hemizygous male pa•
tients had a greater aortic root diameter, thicker inter•
ventricular septum and greater ventricular mass than 
did heterozygous female patients. Left ventricular mass 
Fabry's disease is an X-linked recessive inborn error of 
glycosphingolipid metabolism. The deficient activity of the 
enzyme alpha-galactosidase A results in the accumulation 
of a neutral glycosphingolipid, globotriaosylceramide. pri•
marily in the vascular endothelial lysosomes as well as in 
lysosomes of the kidneys, cardiac muscle and heart valves 
(1,2). The disease is progressive, with symptoms becoming 
more severe with increasing age in hemizygous male pa•
tients, whereas heterozygous female patients are usually 
asymptomatic or have only mild manifestations of the dis•
ease, Although cardiac involvement is not always clinically 
apparent, it is a constant pathologic feature (3), Glyco-
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per square meter of body surface area correlated well 
with clinical disease severity (r = 0.68, P < 0.05), sug•
gesting progressive glycosphingolipid deposition. Older 
heterozygotes (>25 years old) had more severe evidence 
of cardiac disease than did younger male patients. Al•
though mitral valve prolapse was identified in 12 (54%) 
of 23 male hemizygotes and in 7 (58%) of 12 female 
heterozygotes, its presence did not correlate with clinical 
disease severity or other echocardiographic variables. 
Therefore, echocardiographic evidence of Fabry's dis•
ease appears to correlate with age-related disease sever•
ity and may be a useful noninvasive marker to follow 
disease progression and possible regression when ap•
propriate therapy becomes available. 
(1 Am Call CardioI1986;7:1157-61) 
sphingolipid deposition occurs in the cardiac conduction 
system. myocardium, aorta and valve leaflets resulting in 
conduction abnormalities, congestive. restrictive or hyper•
trophic cardiomyopathy. degeneration of the walls of the 
ascending aorta and mitral insufficiency (4-6), Progressive 
vascular disease of the heart, kidney or central nervous 
system, which is the usual cause of death, occurs in the 
third to fifth decades of life, 
In this study we attempted to determine whether cardiac 
abnormalities in Fabry's disease, especially of the mitral 
valve, can be detected echocardiographically and whether 
they correlate with disease severity or progression of disease 
with age. or both, 
Methods 
Study patients. Thirty-five patients with Fabry's dis•
ease were studied: 23 male hemizygotes (aged 28,6 ± 14 
years) and 12 female heterozygotes (aged 31. 4 ± 6 years), 
Three additional patients, one heterozygote with concomi•
tant hypertrophic cardiomyopathy and two hemizygotes with 
blood pressure greater than 140/90 mm Hg, were excluded. 
Each patient underwent clinical evaluation (including car-
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Table 1. Comparison of Echocardiographic Variables Between Hemizygous Male and 
Heterozygous Female Patients With Fabry's Disease 
Hemizygous Heterozygous 
Males Females p Value 
No, of patients 23 12 
Age (yr) 28.6 ± 14 31.4 ± 6.2 NS 
LA (cmlm2) 1.9 ± 0.3 1.9 ± 0.4 NS 
AD (cmlm2) 2.1 ± 0.3 1.7 ± 0.2 <0.001 
IVS (mm) 11.1 ± 3.0 8.8 ± 1.0 <0.02 
LVPW (mm) 10.9 ± 2.9 9.2 ± 1.3 <0.06 
EDD (mm) 45.4 ± 6.7 44.6 ± 5.2 NS 
ESD (mm) 29.2 ± 6.3 29.3 ± 4.6 NS 
FS 0.36 ± 0.07 0.34 ± 0.06 NS 
Mass/BSA (g/m2) 122.3 ± 42.6 86.1 ± 14.3 <0.01 
All data are expressed as mean ± SD. AD = aortic diameter; EDD = end-diastolic dimension; ESD = 
end-systolic dimension; FS = fractional shortening; IVS = interventricular septal thickness; LA = left atrial 
diameter; L VPW = left ventricular posterior wall thickness; Mass/BSA = mass divided by body surface area; 
NS = not significant. 
diac auscultation by a cardiologist) and electrocardio•
graphic, echocardiographic and laboratory examinations. Each 
hemizygote had typical clinical manifestations of Fabry's 
disease, essentially no detectable levels of alpha-galacto•
sidase A activity in plasma, isolated leukocytes and cultured 
skin fibroblasts and elevated urinary and plasma globotri•
aosylceramide levels. Heterozygous female patients had in•
termediate levels of alpha-galactosidase A activity. 
Echocardiography. Echocardiograms were performed 
in the supine position using either an A TL Mark 6000 two•
dimensional mechanical sector scanner or an Irex 
ContinuTrace M-mode system. Two-dimensional guidance 
was utilized to obtain optimal M-mode beam orientation in 
all but five patients who were studied before the introduction 
of two-dimensional echocardiography in this institution. 
Measurements were made using the leading edge method 
in accordance with the recommendations of the American 
Society of Echocardiography (7). Fractional shortening was 
calculated by dividing the difference between the end-dia•
stolic dimension and the end-systolic dimension by the end-
diastolic dimension. Left ventricular (LV) mass was cal•
culated from the M-mode echocardiogram using the for•
mulas (8,9): 
LV maSSecho = (L VID + 2MMT3) - L VID3 
and 
LV mass.ctu•l = 0.7 LV massecho + 2.4 g, 
where L VID is the left ventricular internal dimension and 
MMT is the mean myocardial thickness (the sum of left 
ventricular posterior wall and septal thickness divided 
by 2). 
The mitral valve was examined for abnormal echocar•
diographic patterns. Because they are well-established, M•
mode criteria were used as the standard to define the pres•
ence of mitral prolapse. Mitral valve prolapse was defined 
as either 1) late systolic posterior motion of one or both 
leaflets, or 2) holosystolic hammocking with the maximal 
posterior excursion of one leaflet at least 3 mm below the 
C-D line, or both. A redundant mitral valve was defined as 
more than three parallel systolic mitral echoes. Physiologic 
Table 2. Comparison of Echocardiographic Variables Between Male Hemizygotes With Fabry's 
Disease Younger and Older Than 25 Years 
Fabry's Disease 
Normal Adults >25 yr <25 yr p Value 
No. of subjects 14 8 15 
AD (cmlm2) 2.0 to 3.7 2.2 ± 0.3 2.0 ± 0.3 NS 
LA (cmlm2) 1.9 to 4.0 1.9 ± 20 1.9 ± 0.4 NS 
IVS (mm) 6 to II 9 ± 1.8 12.2 ± 3.0 <0.02 
LVPW (mm) 6 to 11 8.4 ± 1.8 12.3 ± 2.3 <0.001 
Mass/BSA (g/m2) 94.6 ± 18.6 138.1 ± 44.7 <0.02 
Age (yr) 12 ± 3.7 37 ± 8 <0.001 
State 1.9 ± 1.6 3.13 ± 1.5 <0.02 
Gal 0.33 ± 0.15 0.31 ± 0.2 NS 
Gal = activity of enzyme alpha-galactosidase A; State = clinical state based on evidence of disease, as 
discussed in text; other abbreviations as in Table I. 
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maneuvers were not routinely used to evoke prolapse. All 
echocardiograms were read blindly by three reviewers, with 
the consensus opinion taken. Interobserver agreement was 
greater than 95%. Echocardiograms were performed as part 
of a series of screening tests before confirmation of the 
presence or absence of Fabry's disease and were interpreted 
without knowledge of the other test results. 
Control group. The results from the patients with Fa•
bry's disease were then compared with data in an age-matched 
control group consisting of 40 men 25 to 44 years old: 20 
with mitral valve prolapse and 20 normal volunteers. There 
were no other echocardiographic differences between these 
two groups. The findings from our female patients were 
compared with a similarly composed age-matched normal 
control group. 
Classification of disease severity. A disease severity 
scale (0 to 4 +) was established (by R.J.D.) based on the 
extent of clinical end-organ involvement, that is, severity 
of renal, cardiac and cerebrovascular manifestations, and 
applied without knowledge of the results of the echocar•
diogram. The scale was interpreted as follows: 0 = asymp•
tomatic; 1 = mild, occasional acroparesthesia and angio•
keratoma only; 2 = mild to moderate clinically symptomatic; 
3 = mild to moderate clinically symptomatic renal, cardiac 
or cerebrovascular involvement, or both, without clinical 
disability; 4 = clinically significant disease, namely, renal 
changes on computed axial tomography or ultrasound, or 
clinical renal disease; 5 = severe clinical disease, end-stage 
renal disease. 
Statistical analysis. Quantitative differences between 
the different subgroups were evaluated by Student's t tests; 
qualitative differences were evaluated by the chi-square sta•
tistic. The hypotheses that two variables were significantly 
correlated were tested by least-squares linear regression 
analysis. Group data are expressed as mean ± SD. Dif•
ferences between patient and control groups were tested by 
the t test for independent variables. 
Results 
Echocardiographic findings. There were distinct echo•
cardiographic differences between clinically affected hemi•
zygous male patients and the clinically asymptomatic het•
erozygous female patients (Table 1). Male hemizygotes had 
a significantly greater aortic root diameter corrected for body 
surface area (2.07 ± 0.3 versus 1.69 ± 0.2 cmlm2, p < 
0.001), thicker interventricular septum (11.1 ± 3 versus 
8.8 ± 1 mm, p < 0.02) and greater left ventricular mass/ 
body surface area (122.2 ± 43 versus 86.1 ± 14 g/m2, 
p < 0.01) than female heterozygotes. Hemizygotes were 
similar to heterozygotes with regard to left atrial size (1.92 
± 0.3 versus 1.92 ± 0.4 mmlm2, p = NS), left ventricular 
posterior wall thickness (10.9 ± 0.3 versus 9.2 ± 1 mm, 
p = 0.06), left ventricular end-diastolic dimension (45.4 
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± 7 versus 44.6 ± 5 mm, p = NS), systolic dimension 
(29.2 ± 6 versus 29.3 ± 5 mm, p = NS) and fractional 
shortening (0.36 ± 0.07 versus 0.34 ± 0.06, P = NS). 
Left ventricular mass. Importantly, left ventricular mass 
per square meter correlated well with clinical disease se•
verity in all hemizygotes (r = 0.68, P < 0.05). Because 
Fabry disease progresses with age, the male patients were 
arbitrarily classified into two groups: those older and those 
younger than 25 years (Table 2). The older male hemizy•
gotes had a thicker interventricular septum (12.2 ± 3 versus 
9.0 ± 1.8 mm, p < 0.02), left ventricular posterior wall 
02.3 ± 2.3 versus 8.4 ± 1.8 mm, p < 0.001) and mass/ 
body surface area (138.1 ± 45 versus 94.6 ± 19 g/m2, 
p < 0.02). To exclude the possibility that the increased wall 
thickness was age related, hemizygotes older than 25 years 
old (15 patients; mean age 37 ± 8 years, range 29 to 48) 
were compared with an age-matched control group: inter•
ventricular septum was thicker in hemizygote patients (p < 
0.001), as was left atrial size (p < 0.01), left ventricular 
posterior wall thickness (p < 0.001) and aortic root size 
(p < 0.001). Myocardial ultrasound reflectance was not 
altered, as has been reported in another infiltrative disease, 
amyloidosis (8). As expected, female heterozygotes did not 
differ from the control group in any of the measured echo•
cardiographic variables. 
Mitral valve abnormalities. Mitral valve prolapse was 
identified in 12 (52%) of the 23 male hemizygotes and in 
7 (58%) of the 12 female heterozygotes. Cardiac auscul•
tation (specifically the presence of a mitral click) correlated 
well with echocardiographic findings of mitral valve pro•
lapse. A redundant mitral valve was seen in 14 of the re•
maining 16 patients: 10 of 11 hemizygotes and 4 of 5 het•
erozygotes. A totally normal mitral valve was seen in only 
one patient, a female heterozygote. There was no correlation 
between the presence or absence of mitral valve abnormal•
ities and the clinical severity of Fabry's disease. There was 
no correlation between the mitral valve abnormalities and 
other echocardiographic variables for either hemizygotes or 
heterozygotes. 
Electrocardiography. Routine electrocardiography was 
less accurate than echocardiography in detecting abnor•
malities. In male hemizygotes, electrocardiography had a 
sensitivity of only 0.64 and a specificity of 0.88 for the 
detection of left ventricular hypertrophy. Additionally, two 
patients with mild concentric hypertrophy had an electro•
cardiographic pattern of an inferior wall myocardial infarc•
tion. 
Discussion 
Mitral valve involvement. Cardiac involvement is a major 
morbid manifestation of Fabry's disease (1-6). Pathologi•
cally, the mitral valve is the most common valve involved. 
Desnick et al. (2) reported pathologic evidence of inter-
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chordal hooding with thickening of the mitral valve leaflets 
and papillary muscles. Ultrastructural examination of the 
cardiac valves revealed electron-dense inclusion bodies in 
lysosomes consistent with biochemical analyses which re•
vealed markedly increased concentrations of globotriaosyl•
ceramide in the mitral valve. 
Several other genetic diseases have also been associated 
with mitral valve prolapse. These include Marfan's syn•
drome, Ehlers-Danlos syndrome, pseudoxanthoma elasti•
cum, Duchenne's muscular dystrophy, Turner's syndrome, 
Noonan's syndrome, osteogenesis imperfecta and myotonic 
dystrophy. Other lysosomal storage diseases have mitral 
valve involvement including mucopolysaccharidosis types 
I and II, GMI gangliosidosis type 1 and GM2 gangliosidosis 
type 2. In addition, mitral valve prolapse has been associated 
with connective tissue abnormalities, coagulopathies and 
thoracoskeletal disorders (10-12). 
The high prevalence of echocardiographically docu•
mented mitral valve prolapse and redundancy in Fabry's 
disease has not been previously appreciated. In the present 
study of 35 patients, 54% had mitral valve prolapse. The 
incidence of mitral valve abnormalities was similar in both 
hemizygotes and heterozygotes. Importantly, there was no 
correlation between disease severity, age or other echocar•
diographic variables and the presence or absence of mitral 
valve abnormalities. The echocardiographic mitral valve ab•
normalities may be a marker of glycosphingolipid deposi•
tion, creating a thicker but mobile valve with a tendency to 
prolapse into the left atrium. Because maneuvers were not 
performed routinely, the propensity for the redundant valves 
to prolapse could not be determined. In the single previous 
echocardiographic study (13), only I of 32 patients with 
Fabry's disease was reported to have an abnormal mitral 
valve. However, in that study, only a dedicated M-mode 
machine was utilized, emphasis was placed on chamber 
dimensions and mitral valve imaging was not pursued when 
the study was technically difficult. In the present study, both 
M-mode and two-dimensional equipment were used, thereby 
improving the ability to fully image the mitral valve even 
in difficult cases. 
Ventricular abnormalities. Another significant echo•
cardiographic feature of Fabry's disease was the increased 
left ventricular wall thickness and greater ventricular mass 
with increasing age and disease severity in hemizygotes. 
Bass et al. (13) also found that the majority of hemizygotes 
studied pathologically had increased wall thickness, which 
probably represents progressive glycosphingolipid deposi•
tion in the myocardium. It is unlikely that mitral valve 
prolapse alone could account for these changes, because the 
mitral prolapse in this study was not associated with clin•
ically significant mitral regurgitation. Therefore, left ven•
tricular wall thickness and mass, readily obtainable by echo•
cardiography, may be a noninvasive marker to estimate 
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clinical Fabry's disease severity, and may be used to follow 
disease progression and possible regression in response to 
therapeutic interventions. However, sequential echocardio•
graphic studies, and potentially, endomyocardial biopsies 
will be necessary to document the rate of progression of 
ventricular mass and wall thickness to determine how closely 
they correlate with overall disease severity, and whether the 
cardiac abnormalities may predict the clinical course. In•
terestingly, as documented in other disease states, the elec•
trocardiogram was not as helpful as the echocardiogram in 
detecting left ventricular hypertrophy (14). 
Conclusions. Patients with Fabry's disease have a high 
incidence of mitral valve abnormalities as detected by echo•
cardiography. In addition, left ventricular wall thickness and 
mass appear to correlate with the severity of their disease. 
It is therefore recommended that patients with Fabry's dis•
ease undergo careful auscultation and echocardiographic ex•
amination to evaluate the presence of mitral valve abnor•
malities and increased wall thickness. These findings may 
serve as noninvasive markers of the disease when thera•
peutic interventions are available. 
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